Somatropin + Somatropin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Growth Hormone Deficiency
Conditions
Growth Hormone Deficiency
Trial Timeline
Mar 1, 2004 → Apr 1, 2008
NCT ID
NCT00191165About Somatropin + Somatropin
Somatropin + Somatropin is a phase 3 stage product being developed by Eli Lilly for Growth Hormone Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00191165. Target conditions include Growth Hormone Deficiency.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00191165 | Phase 3 | Completed |
| NCT00570011 | Phase 3 | Completed |
Competing Products
20 competing products in Growth Hormone Deficiency